Literature DB >> 10632249

Parents' utilities for outcomes of occult bacteremia.

J E Bennett1, W Sumner, S M Downs, D M Jaffe.   

Abstract

OBJECTIVE: To describe parents' values for outcomes of occult bacteremia using utility assessment, a quantitative method that incorporates risk preference.
DESIGN: Computer-based utility assessment interview.
SETTING: Urban children's hospital pediatric emergency department with 50 000 visits annually. PARTICIPANTS: Convenience sample of parents presenting with a child between 3 and 36 months. MAIN OUTCOME MEASURE: Parents' utility values for 8 outcomes from treatment of occult bacteremia: blood drawing, localized infection, hospitalization for antibiotics, meningitis with recovery, meningitis resulting in deafness, minor brain damage, severe brain damage, and death.
RESULTS: Ninety-four subjects successfully completed the interview. Mean utilities were 0.9974 for blood drawing, 0.9941 for local infection, 0.9921 for hospitalization, 0.9768 for meningitis with recovery, 0.8611 for deafness, 0.7393 for minor brain damage, 0.3903 for severe brain damage, and 0.0177 for death. All values were significantly different from those that immediately preceded and succeeded (P<.0001), except for local infection vs hospitalization (P = .14). Median utilities for blood drawn, local infection, and hospitalization were 1. There were no significant differences among utilities of parents who presented with a febrile child (temperature > or =39 degrees C), or an afebrile child (temperature <39 degrees C). There were also no significant differences among utilities regardless of whether parents had children with prior experience with the outcomes.
CONCLUSIONS: Assessment of utilities for outcomes of occult bacteremia yielded extremely high mean and median values for outcomes without permanent sequelae. This suggests that parents presenting to an emergency department may rationally prefer painful transient experiences, including venipuncture, for their children rather than risk even rare chances of severe outcomes.

Entities:  

Mesh:

Year:  2000        PMID: 10632249

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  34 in total

1.  Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.

Authors:  Chun-Yi Lu; Ching-Hu Chung; Li-Min Huang; Eliza Kruger; Seng-Chuen Tan; Xu-Hao Zhang; Nan-Chang Chiu
Journal:  Cost Eff Resour Alloc       Date:  2020-08-28

2.  Quality of life and congenital heart defects: comparing parent and professional values.

Authors:  Rachel L Knowles; Ingolf Griebsch; Catherine Bull; Jacqueline Brown; Christopher Wren; Carol Dezateux
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

3.  Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants.

Authors:  Hua Zhou; Jinchun He; Bin Wu; Datian Che
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

4.  Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.

Authors:  Guijun Ning; Zundong Yin; Yixing Li; Huaqing Wang; Weizhong Yang
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

5.  Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials.

Authors:  Michael M Ward; Lori C Guthrie
Journal:  Rheumatology (Oxford)       Date:  2016-10-27       Impact factor: 7.580

Review 6.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

Review 7.  Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review.

Authors:  Laura Rodríguez; Marie-Chantal Ethier; Bob Phillips; Thomas Lehrnbecher; John Doyle; Lillian Sung
Journal:  Support Care Cancer       Date:  2012-04-29       Impact factor: 3.603

8.  Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women.

Authors:  Jing Xu; Fangjun Zhou; Carrie Reed; Sandra S Chaves; Mark Messonnier; Inkyu K Kim
Journal:  Vaccine       Date:  2016-05-06       Impact factor: 3.641

9.  Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China.

Authors:  Caixia Wang; Li Su; Qiuling Mu; Xueyan Gu; Xuejun Guo; Xuxia Wang
Journal:  Hum Vaccin Immunother       Date:  2021-02-12       Impact factor: 3.452

10.  Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.

Authors:  Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds
Journal:  BMJ       Date:  2012-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.